SAGE Therapeutics (NASDAQ: SAGE) stock price dropped significantly pre-market Wednesday after the company, alongside partner Biogen, announced disappointing results from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot List

SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 FailsJuly 24, 2024 7:43 AM Form 8-K Sage Therapeutics, Inc. For: Jul 24July 24, 2024 6:40 AM SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324July 24, 2024 6:32 AM Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential TremorJuly 24, 2024 6:30 AM